• Clinical Trials - Colorectal cancer

    Study Objective Contact
    CALGB/SWOG C80702: A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer [LCID Study Number: 2010-075] This study is being done to evaluate the effects (good and bad) of different chemotherapy treatments. One of the common combinations of chemotherapy drugs used to treat your type of cancer includes 5-fluorouracil (also called 5-FU), leucovorin and oxaliplatin, and is also called “FOLFOX”. At the present time, the Food and Drug Administration (FDA) has approved each of these drugs as treatment for colon cancer. FOLFOX is a standard treatment used to prevent colon cancer from coming back (recurrence). Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    Open-Label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to anti-EGFR Monoclonal Antibodies [LCID Study Number: 2014-022] The purpose of this study is to investigate whether patients with metastatic colorectal cancer who have previously received treatment with drugs such as Erbitux and Vectibix benefit from treatment with two different doses of an investigational drug and to compare its effects with either one of two existing cancer treatments or best supportive care (treatment for the symptoms of disease but without any anti-cancer treatment). Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    Pre-Operative Risk Adjustment of the Vulnerable Elders with Colon and Rectal Cancer [LCID Study Number: 2014-035] The purpose of the study is to develop questions that can be asked of all older cancer patients to better understand their risk for surgery when diagnosed with colon and rectal cancer or polyp. The assessments will take place at Lahey Hospital & Medical Center’s Department of Colon and Rectal Surgery. Prior to surgery and again at 1 and 3 months after the surgery, subjects will be asked questions about their daily activities, any other medical problems they have, their mood, nutrition, support they get from family members and friends, and any problems they might be having with their memory. Subjects will be observed for their ability to rise from a chair and walk 10 feet and return to the chair. Principal Investigator(s):
    Todd D. Francone, MD, MPH

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    .
    S1406, Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer [LCID Study Number: 2014-086CIRB] The purpose of this study is to compare any good and bad effects of using vemurafenib along with the usual chemotherapy (cetuximab and irinotecan), to using the usual chemotherapy alone in subjects with colorectal cancer that has spread beyond the colon or rectum. The study drug, vemurafenib, blocks the activity of a protein called the B-raf protein; this protein is involved in sending signals to the cells which direct cell growth. The study drug, vemurafenib, blocks the activity of the B-raf protein only when a mutation is present. Therefore, only patients whose tumors have a BRAF mutation are eligible for this study. Tissue from patients’ surgery or biopsy will be used to test for the BRAF mutation. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett,
    Julie Roache.